Eko Health is reinventing one of medicine's most iconic tools, the stethoscope, transforming it from a passive listening device into an AI-powered instrument for early detection of cardiovascular and pulmonary disease. Its product line includes the flagship CORE 500 digital stethoscope, the co-branded 3M Littmann CORE digital stethoscope, and a CORE digital attachment that upgrades existing stethoscopes. Each device combines digital audio amplification, active noise cancellation, waveform visualization, and a 3-lead ECG, capturing far richer data than a traditional acoustic exam.
The real differentiator is the layer of FDA-cleared AI that interprets what the device hears and records. Eko's algorithms can identify structural heart murmurs, atrial fibrillation, and reduced ejection fraction, flagging signs of disease that are easy to miss at the point of care. The company says providers using Eko are roughly twice as likely to detect heart disease, a claim grounded in real-world studies and a body of more than 70 peer-reviewed publications, including work published in The Lancet.
Eko operates as a platform business spanning primary care, cardiology, telehealth, life sciences, and even veterinary medicine through a partnership with Boehringer Ingelheim. Its SENSORA cardiac disease detection platform has secured CMS reimbursement, an important milestone that supports adoption across U.S. health systems, and the company has sold more than 750,000 devices to date.
Eko Health raised a $41 million Series D in 2024 led by ARTIS Ventures, Highland Capital Partners, NTTVC, and Questa Capital, with strategic participation from Double Point Ventures, EDBI, and LG Technology Ventures, bringing its lifetime funding to roughly $165 million. The capital supports continued expansion of its AI algorithms and global reach, including in Singapore and South Korea, as Eko works to make AI-assisted cardiopulmonary screening a routine part of every physical exam.